C3BS CQR 1

Drug Profile

C3BS CQR 1

Alternative Names: Autologous cardiac progenitor stem cell therapy - Celyad; Bone marrow derived mesenchymal cardiopoietic cells - Celyad; C-Cure; C3BR-CQR-1; C3BS-CQR-1; Congestive heart failure cardiopoietic regenerative therapy - Celyad

Latest Information Update: 01 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cardio3 BioSciences
  • Developer Celyad
  • Class Heart failure therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Chronic heart failure

Most Recent Events

  • 01 Sep 2017 C3BS CQR 1 is still at phase III development stage for Chronic heart failure in European Union, Switzerland, Israel and Serbia (Intracoronary)
  • 11 May 2017 C3BS CQR 1 receives Fast track status from the US FDA for Chronic heart failure
  • 09 Sep 2016 Celyad completes the phase III CHART-1 trial in Chronic heart failure in Sweden, Ireland, Croatia, the United Kingdom, Belgium, Serbia, Bulgaria, Hungary, Spain, Italy, Poland, Switzerland and Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top